BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11598367)

  • 21. [A case of ovarian cancer stage IV and advanced rectal cancer responding to paclitaxel/carboplatin].
    Kawaguchi R; Furukawa N; Morimoto Y; Ohi M; Osawa T; Koike H; Miyake T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):619-22. PubMed ID: 15114712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
    Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
    Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-Existing Ovarian Mucinous Cystadenocarcinoma with Mature Cystic Teratoma: A Rare Case Report.
    Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Piyawong W; Himakhun W; Bhamarapravatana K
    J Med Assoc Thai; 2016 Jul; 99 Suppl 4():S281-6. PubMed ID: 29927186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline mucinous tumour with mural nodule of signet ring adenocarcinoma.
    Ong NC; Ostör AG
    Aust N Z J Obstet Gynaecol; 2002 Nov; 42(5):561-2. PubMed ID: 12495115
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.
    Takei Y; Suzuki M; Ohwada M; Saga Y; Kohno T; Machida S; Sato I
    Oncol Rep; 2003; 10(4):951-5. PubMed ID: 12792751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
    Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
    Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos HP; Efstathiou E; Salamalekis E; Farmakis D; Skarlos D; Briasoulis E; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2005 May; 97(2):436-41. PubMed ID: 15863142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of ovarian cancer with metastatic tumor in the liver with paclitaxel and carboplatin systemic chemotherapy was very effective].
    Honda T; Ishii T; Kawashima S; Fukasawa H; Iwamoto H; Shimazu Y; Yamanaka T; Shoda T; Kitamura T; Hashi A; Hirata S; Hoshi K
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1923-7. PubMed ID: 11729489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Selecting postoperative chemotherapy regimen and optimizing therapy cycle for stage II-IV ovarian epithelial carcinoma].
    Huang YW; Li YJ; Li MD
    Ai Zheng; 2005 Aug; 24(8):994-7. PubMed ID: 16086880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.
    Adachi S; Itani Y; Ito K; Noda T; Shintani M; Saito K; Furukawa N; Tomii Y
    Oncol Rep; 2001; 8(1):27-31. PubMed ID: 11115564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A
    Oncology; 2005; 69(4):348-53. PubMed ID: 16293974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.